




PHARMACEUTICAL 2021

ALPINE IMMUNE SCIENCES INC.
Rank 235 of 402





RealRate

PHARMACEUTICAL 2021

ALPINE IMMUNE SCIENCES INC. Rank 235 of 402



The relative strengths and weaknesses of ALPINE IMMUNE SCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALPINE IMMUNE SCIENCES INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 32% points. The greatest weakness of ALPINE IMMUNE SCIENCES INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 63% points.

The company's Economic Capital Ratio, given in the ranking table, is 70%, being 23% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	107,101
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	41,167
Liabilities, Non-Current	40,765
Other Assets	35,204
Other Compr. Net Income	43
Other Expenses	769
Other Liabilities	0
Other Net Income	245
Other Revenues	10,668
Property and Equipment	1,785
Research and Development	27,185
Selling, General and Administrative Expense	10,899

Output Variable	Value in 1000 USD
Assets	144,090
Liabilities	81,932
Expenses	38,853
Revenues	10,668
Stockholders Equity	62,158
Net Income	-27,940
Comprehensive Net Income	-27,918
Economic Capital Ratio	70%